Trial Search Results

18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules

This phase II trial studies how well 18F-FSPG positron emission tomography (PET)/computed tomography (CT) work in diagnosing early lung cancer in patients with lung nodules. PET imaging with an imaging agent called 18F-FDG is often used in combination with a PET/CT scanner to evaluate cancers.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Andrei Iagaru

Collaborator: Boston University

Stanford Investigator(s):

Intervention(s):

  • Procedure: Computed Tomography
  • Drug: Fludeoxyglucose F-18
  • Drug: Fluorine F 18 L-glutamate Derivative BAY94-9392
  • Procedure: Positron Emission Tomography

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - Pulmonary nodule between the size of 7 to 30 mm. Subjects with multiple nodules may be
   eligible if the dominant nodule is 7 to 30 mm

   - Undergoing standard of care 18F-FDG PET imaging (for indeterminate pulmonary nodule)

   - Current or former cigarette smoker, with >= 20 pack years

   - Documented informed consent

Exclusion Criteria:

   - History or previous diagnosis of lung cancer

   - Cancer diagnosis within the last 5 years

   - Pregnant or nursing

Ages Eligible for Study

45 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Mahima Goel
650-723-0371
Recruiting